Bold claim: A breakthrough in treating a devastating genetic disease may be closer than we think. Researchers from Mass General Brigham and the Broad Institute have pinpointed a potential drug target for Friedreich’s ataxia (FA), offering a clearer path toward new, disease-modifying therapies.
FA is a rare but severe condition typically diagnosed in childhood or adolescence, with many patients living only into their 30s or 40s. There is no widely approved treatment that changes the disease’s course, and current options don’t help everyone. In this new work, the researchers identify a genetic modifier of FA that could be exploited to develop better medicines. The findings are published in Nature and have been independently corroborated by a biochemical study in the same issue.
The research team uses humble yet powerful model systems to unravel FA biology. Their approach builds on prior work showing that reduced oxygen levels (hypoxia) can partially rescue frataxin loss in human cells, worms, and mice. Instead of advocating hypoxia as a therapy, they employ it as a tool to uncover genetic suppressors that can compensate for frataxin deficiency.
Lead author Joshua Meisel described the significance: the suppressor they’ve identified, FDX2, is a protein that could be targeted with conventional drugs, making this discovery particularly actionable. The team tested their ideas in a simple model organism, C. elegans, creating frataxin-deficient worms. Under low-oxygen conditions, these worms survive, and through random genetic changes they isolated a subset that could grow even when oxygen was not limited. Sequencing these survivors revealed mutations in two mitochondrial genes, FDX2 and NFS1.
To validate the findings, the researchers used sophisticated genetic engineering, laboratory biochemistry, and experiments in human cells and mice to show that certain alterations in FDX2 and NFS1 can bypass the need for frataxin. This bypass supports the continued production of essential iron-sulfur clusters, which are critical for energy production and multiple cellular functions. Notably, too much FDX2 can hinder this process, while reducing FDX2—either by mutation or by removing one gene copy—restores iron-sulfur cluster synthesis and improves cell health.
Senior author Vamsi Mootha emphasized the delicate balance at play: when frataxin is scarce, dialing FDX2 down a notch can be beneficial, but overall biochemical homeostasis requires careful tuning. In a mouse FA model, lowering FDX2 levels also improved neurological symptoms, suggesting real therapeutic potential.
Together, the work implies that precisely adjusting the activity of proteins interacting with frataxin could mitigate the disease’s effects. However, the authors caution that the optimal balance between frataxin and FDX2 may vary with context, and more work is needed to understand how this balance is regulated in people. Before any human trials, future studies must assess safety and efficacy in additional preclinical models.
Authorship includes Meisel, Mootha, Ruvkun, and colleagues Pallavi R. Joshi, Amy N. Spelbring, Hong Wang, Sandra M. Wellner, Presli P. Wiesenthal, Maria Miranda, Jason G. McCoy, and David P. Barondeau. The work is supported by funding from the Friedreich’s Ataxia Research Alliance, NIH, the Robert A. Welch Foundation, and other organizations. Some authors hold patents or equity linked to the research; disclosures note ties to Falcon Bio and 5am Ventures.
What this means for FA: for the first time, scientists have a tangible target (FDX2) that can be modulated with drugs to help cells cope with frataxin loss. If safety and effectiveness hold up in further studies, this could become the basis for a new class of therapies that address the disease mechanism rather than just alleviating symptoms. But questions remain: how precisely should FDX2 be modulated in humans, and when during disease progression would intervention be most beneficial? As always with genetic diseases, patient diversity matters—what works for one individual may not for another. Share your thoughts: Do you think targeting mitochondrial machinery is a promising strategy for FA, or should efforts focus elsewhere? And what considerations would you want researchers to prioritize in translating these findings to clinical trials?
